2012
DOI: 10.1248/bpb.35.666
|View full text |Cite
|
Sign up to set email alerts
|

The Therapeutic Effect of Chelidonic Acid on Ulcerative Colitis

Abstract: Chelidonic acid (CA), a constituent of Chelidonium majus L., has many pharmacological effects, including mild analgesic and antimicrobial effects. However, the effects of CA on intestinal inflammation and the molecular mechanisms responsible are poorly understood. The aim of this study was to investigate the protective effects of CA against dextran sulfate sodium (DSS)-induced ulcerative colitis (UC). Mice treated with DSS displayed obvious clinic signs, such as, body weight loss and a shortening of colon leng… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
23
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 43 publications
(24 citation statements)
references
References 39 publications
0
23
0
Order By: Relevance
“…Mostly, the total extracts or isolated alkaloids were tested, but in our opinion, other components such as hydroxycinnamic derivatives, flavonoids and chelidonic acid are likely to contribute significantly. Chelidonic acid [45] was efficient in mouse models of ovoalbumin-elicited allergic rhinitis (Oh et al, 2011 ) and ulcerative colitis (Kim et al, 2012 ). This compound also attenuated inflammatory responses by reducing levels and gene expression of several mediators and enzymes in colon tissues (COX-2, HIF1α, PGE 2 ) and in allergic mice (IL-4, IL-1β, COX-2, caspase-1, and increase of IFN-γ).…”
Section: Pharmacological Activities and Clinical Evidencementioning
confidence: 99%
“…Mostly, the total extracts or isolated alkaloids were tested, but in our opinion, other components such as hydroxycinnamic derivatives, flavonoids and chelidonic acid are likely to contribute significantly. Chelidonic acid [45] was efficient in mouse models of ovoalbumin-elicited allergic rhinitis (Oh et al, 2011 ) and ulcerative colitis (Kim et al, 2012 ). This compound also attenuated inflammatory responses by reducing levels and gene expression of several mediators and enzymes in colon tissues (COX-2, HIF1α, PGE 2 ) and in allergic mice (IL-4, IL-1β, COX-2, caspase-1, and increase of IFN-γ).…”
Section: Pharmacological Activities and Clinical Evidencementioning
confidence: 99%
“…Besides, C. majus contains flavonoids, saponins, vitamins (e.g., vitamin A and C), mineral elements, sterols, and acids and their derivatives [ 5 ]. Pharmacological properties ascribed to C. majus include anti-bacterial [ 6 ], anti-inflammatory [ 7 ], anti-viral [ 8 ], anti-fungal [ 9 ], anti-protozoal and radioprotective [ 10 ], hepatoprotective [ 11 ], natriuretic and antidiuretic and also anti-alzheimer effects [ 12 ]. In recent years, an anti-cancer potential of various C. majus alkaloids including chelidonine, sanguinarine, berberine, chelerythrine and coptisine, has been demonstrated, and the interest in Greater celandine as a natural crude drug has increased significantly [ 4 , 13 , 14 , 15 , 16 ].…”
Section: Introductionmentioning
confidence: 99%
“…Previous research has demonstrated that ruscogenin (P37) can inhibit LPS-induced lung inflammation by down-regulating intercellular adhesion molecule-1 and suppressing NF-κB activation in anti-inflammatory pathways 51 52 . The high levels of chelidonic acid (P8) in RA can reduce dextran sulphate sodium-induced TNF-α production 53 . Our results indicated that ruscogenin (P37) might have positively contribute to the inhibition of IL-1β and IL-6, and chelidonic acid (P8) potentially positively contribute to the suppression of TNF-α.…”
Section: Discussionmentioning
confidence: 99%